Skip to main content

CordenPharma in peptide expansion

CordenPharma has announced the addition of a 3,000-litre solid-phase peptide synthesis (SPPS) vessel at its GMP API facility in Boulder, Colorado. This site, which was formerly owned by Roche, already has a 10,000-litre SPPS vessel and a 100 cm high-pressure reverse phase purification column, and is claimed to have the largest capacity of any peptide API facility.

The investment was made in response to what the company called “a large spike in the demand for peptide APIs, and to continue an overall growth strategy”. The vessel will enable it to manufacture a complex long peptide with a 400 kg output per single batch, according to Dr Matthieu Giraud, director of the Global Peptides, Lipids & Carbohydrates platform.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.